Significantly increased risk for tardive dyskinesia seen with doses >75 mg/day at last prescription and as maximum dose ...

Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...

Investment firm Bain Capital is in talks to acquire Mitsubishi Tanabe Pharma Corp., affiliated to Japan's Mitsubishi Chemical Group ...

The mining giant posted a sharp rise in second-quarter copper production thanks to a jump in output at Escondida, the world's largest copper mine. Shares in the company, once one of China's largest ...

Japan's Mitsubishi Chemical Group has picked U.S. investment fund Bain Capital as the preferred bidder for its pharmaceutical ...

TOKYO -- Japan's Mitsubishi Chemical Group has granted a first-refusal right to U.S. investment fund Bain Capital for the purchase of its pharmaceutical subsidiary Mitsubishi Tanabe Pharma, Nikkei has ...

Mitsubishi Chemical Group is stepping up its efforts to streamline operations by entering negotiations with U.S. investment ...

Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class ...

NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...